Skip to main content
Journal cover image

Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry).

Publication ,  Journal Article
O'Brien, EC; Simon, DN; Roe, MT; Wang, TY; Peterson, ED; Alexander, KP
Published in: Am J Cardiol
June 15, 2015

Elevated low-density lipoprotein cholesterol (LDL-C) is associated with increased risk of myocardial infarction and is a target for disease prevention. The association between initial LDL-C and statin treatment in patients with non-ST-segment elevation myocardial infarction (NSTEMI)/unstable angina pectoris (UAP) has not been well characterized. We explored detailed LDL-C levels and statin treatment in 22,938 patients with NSTEMI/UAP enrolled in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry (2003 to 2006). Patients reporting home statin use or previous cardiovascular disease were excluded. We examined statin receipt at discharge across 4 categories of baseline LDL-C: very low (<70 mg/dl), low (70 to 99 mg/dl), high (100 to 129 mg/dl), and very high (≥130 mg/dl). The largest proportion of patients had LDL-C ≥130 mg/dl (32.6%), followed by LDL-C 100 to 129 mg/dl (32.1%), LDL-C 70 to 99 mg/dl (24.9%), and LDL-C <70 mg/dl (10.4%). Compared with high LDL-C categories, patients in the lowest LDL-C category had their first NSTEMI/UAP event at a significantly older age and had higher rates of other cardiovascular risk factors (including hypertension and diabetes) but were less likely to have a family history of coronary artery disease. Overall, 80.3% of eligible patients with NSTEMI/UAP received statins at discharge, ranging from 63.8% in those with very low LDL-C (<70 mg/dl) to 88.1% in those with very high LDL-C (>130 mg/dl). In conclusion, >1/3 of patients with NSTEMI/UAP had an LDL-C level <100. Those with low LDL-C were older, had more co-morbidities, and were less likely to be prescribed a statin at discharge than those with higher LDL-C.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

June 15, 2015

Volume

115

Issue

12

Start / End Page

1655 / 1660

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Risk Factors
  • Registries
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
O’Brien, E. C., Simon, D. N., Roe, M. T., Wang, T. Y., Peterson, E. D., & Alexander, K. P. (2015). Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry). Am J Cardiol, 115(12), 1655–1660. https://doi.org/10.1016/j.amjcard.2015.03.007
O’Brien, Emily C., DaJuanicia N. Simon, Matthew T. Roe, Tracy Y. Wang, Eric D. Peterson, and Karen P. Alexander. “Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry).Am J Cardiol 115, no. 12 (June 15, 2015): 1655–60. https://doi.org/10.1016/j.amjcard.2015.03.007.
O’Brien, Emily C., et al. “Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry).Am J Cardiol, vol. 115, no. 12, June 2015, pp. 1655–60. Pubmed, doi:10.1016/j.amjcard.2015.03.007.
Journal cover image

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

June 15, 2015

Volume

115

Issue

12

Start / End Page

1655 / 1660

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Risk Factors
  • Registries
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Female